Skip to Content
Translational Research Program (TRP)
Last Updated: 09/28/16

Myeloma SPOREs

Multiple myeloma, a disease of white blood cells, will claim 12,650 lives in 2016 (2.1% of all cancer deaths), according to estimates from the Surveillance, Epidemiology, and End Results (SEER) program. Another 30,330 new cases will be diagnosed in the same year with African Americans having around double the incidence of myeloma compared to that of Americans of European ancestry. While recent improvements in treatment have resulted in a more favorable outlook for patients, five-year survival rates are still unacceptably low: 48.5% based on 2006-2012 data. The first solicitation for myeloma SPORE applications was announced in 2001, applications were reviewed in 2002 and the first award given in 2003.

Dana-Farber Harvard Cancer Institute

Kenneth Anderson, MD [Click Here]
Chief, Division of Hematologic Neoplasia
Dana-Farber Cancer Institute
Department of Medical Oncology
44 Binney Street
Boston, MA 02115
Tel: (617) 632-2144
Fax: (617) 632-2140

For more information on this specific SPORE’s institution, please visit:

Mayo Clinic, Arizona

P. Leif Bergsagel, M.D. [Click Here]
David F. and Margaret T. Grohne Professor of
Novel Therapeutics for Cancer Research
Division of Hematology/Oncology
Professor of Medicine
Mayo Clinic
13400 E. Shea Blvd.
Scottsdale, AZ 85259
Tel: (480) 301-4704

University of Texas/MD Anderson

Robert Orlowski, MD, PhD [Click Here]
MD Anderson Cancer Center
Department of Lymphoma/Myeloma
1515 Holcombe Blvd., Unit 429
Houston, TX 77030-4009
Tel: (713) 792-2860

For more information on this specific SPORE’s institution, please visit: